Aclaris Therapeutics, Inc.
N/A
USD
N/A
N/A
...
Chart
Financials
Description
ACRS Company Description
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
ACRS Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view ACRS Smart Score
Score Breakdown
ACRS Company Description
Show More
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777. Show Less
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of ACRS by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ACRS's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
Twitter
Followers on ACRS's company Twitter account
WallStreetBets
Number of mentions of ACRS in WallStreetBets Daily Discussion
ACRS News
Recent insights relating to ACRS
CNBC Recommendations
Recent picks made for ACRS stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in ACRS
Corporate Flights
Flights by private jets registered to ACRS
Our Analysis